Successful Treatment with Patisiran in Amyloid Polyneuropathy Harboring His90Asn Mutation in the TTR Gene.
Vincenzo Di StefanoPietro GuaraldiFrancesca GigliaIlaria CaniAntonia PignoloLuca CodeluppiPaolo AlongeElena CanaliGiovanni De LisiAda Maria FlorenaEugenia BorgioneFilippo BrighinaPublished in: Brain sciences (2024)
Hereditary transthyretin amyloidosis (hATTR) is a multisystemic, rare, inherited, progressive and adult-onset disease, affecting the sensory-motor nerves, heart, autonomic function, and other organs. There are over 130 mutations known in the TTR gene. The His90Asn mutation has been previously reported in several reports, but its pathogenetic role is still debated. We report two sporadic cases of adult women with a heterozygous His90Asn mutation in TTR gene and neurological involvement extensively investigated. A typical Congo red-positive pathologic deposition of amyloid fibrils in the salivary glands was documented in one subject. Patients were successfully treated with patisiran with a good clinical outcome. These data support a pathogenetic role of His90Asn mutation in hATTR, and suggest early treatment in symptomatic carriers of His90Asn mutation.
Keyphrases
- copy number
- end stage renal disease
- genome wide
- chronic kidney disease
- ejection fraction
- multiple sclerosis
- multidrug resistant
- emergency department
- newly diagnosed
- gene expression
- blood pressure
- squamous cell carcinoma
- heart rate variability
- neoadjuvant chemotherapy
- atrial fibrillation
- lymph node
- peritoneal dialysis
- heart rate
- electronic health record
- prognostic factors
- mass spectrometry
- artificial intelligence
- young adults
- big data
- patient reported outcomes
- brain injury
- deep learning
- atomic force microscopy
- single molecule
- blood brain barrier
- high speed